Proleukin (aldesleukin) / Merck (MSD), Prometheus, Novartis, Roche, Iovance Biotherap, Clinigen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
NCT01909206: A Phase I Trial of Anti-PD-1, Anti-CD137 and TIL

Not yet recruiting
1
24
US
Nivolumab, Anti-PD-1 blocking antibody, BMS-936558, Tumor Infiltrating Lymphocyte (TIL), Cyclophosphamide, Cytoxan, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Fludarabine, Fludara, TIL Infusion, High Dose Interleukin-2 (IL-2), Aldesleukin, Proleukin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Laboratories, National Cancer Institute (NCI)
Metastatic Melanoma
12/16
12/16
NCT03215810: Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed
1
20
US
Tumor-infiltrating Lymphocytes (TIL), TIL, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2), IL2, Proleukin®
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Inc., Stand Up To Cancer, Iovance Biotherapeutics, Inc.
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
02/21
06/23
NCT03260504: Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Terminated
1
6
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1)
University of Washington, Merck Sharp & Dohme LLC, Prometheus Laboratories
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
07/22
07/22
NCT04551885: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
12
US
FT516, Avelumab, Bavencio, Cyclophosphamide, Fludarabine, IL-2, Proleukin, Aldesleukin
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
NCT06236425: TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Recruiting
1
15
US
TBio-4101, Tumor-Infiltrating Lymphocyte, Pembrolizumab, Keytruda, Platinum based chemotherapy, Cisplatin, Carboplatin/5-FU, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Aldesleukin, Interleukin-2, IL-2
H. Lee Moffitt Cancer Center and Research Institute, Turnstone Biologics, Corp.
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
05/26
05/26
ADP-TILIL7, NCT06204991: To Evaluate the Safety and Efficacy of in Patients With Locally Advanced or Metastatic Melanoma

Not yet recruiting
1
10
NA
ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate, Proleukin
Inge Marie Svane, Adaptimmune
Melanoma Stage III, Melanoma Stage IV, Melanoma
03/26
04/27
NCT05676749: C-TIL051 in Non-Small Cell Lung Cancer

Recruiting
1
20
US
C-TIL051, Pembrolizumab, NKTR-255
AbelZeta, Inc., Nektar Therapeutics
Metastatic Non Small Cell Lung Cancer
03/26
08/27

Download Options